All Posts

Nurse Practitioner – Full or Part Time Residential Eldercare Services   🌟 Join Our Exceptional Team as a Nurse Practitioner! 🌟 Are you passionate about providing the highest standard of care to the elderly? Do you thrive in a collaborative and supportive work environment? We have an exciting job opportunity for Nurse Practitioners to join our unique totally mobile general practice dedicated to eldercare. At Residential Eldercare Services, we believe in fostering a dynamic a

From 1 July 2026, Pharmac will take over responsibility for funding medicines used in ambulances. This consultation seeks feedback on changes to the Pharmaceutical Schedule which supports this decision. Bringing ambulance medicines into the Pharmaceutical Schedule will help to ensure a more coordinated approach to funding and procurement decisions for emergency medicines, whether they are used in hospitals, ambulances or by PRIME providers. Under this proposal, we would also

We have made the decision to widen access to brentuximab vedotin for systemic anaplastic large cell lymphoma from 1 April 2026 .  We expect this will improve the lives of around 12-13 people in New Zealand per year.Thank you to all those who provided feedback in response to the consultation, your feedback is appreciated. You can find more information on this decision on the Pharmac website including our responses to key points raised by consultees. Decision to widen access to

Pharmac has made a decision to widen access to Trikafta and Kalydeco, and to fund Alyftrek for the treatment of cystic fibrosis.From 1 April 2026, the following changes will be implemented for people with eligible mutations: Widened access to Trikafta (elexacaftor/tezacaftor/ivacaftor) Widened access to Kalydeco (ivacaftor) Funding of a new medicine, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) This decision follows consultation with people with cystic fibrosis, their fami

Dear Andrea, NEXT WEEK!  Goodfellow Symposium 2026 And while we wait, here are our latest webinars and podcasts:    Functional gastrointestinal conundrums: Utilising the MDT WEBINAR 17 March: The team from Allevia Hospitals will distil key practical tips and demonstrate how a team-based, multidisciplinary approach can help clinicians manage common GI conundrums more effectively.    Register here   Adult ADHD in practice: A clinical Q&A  WEBINAR 19 March: Join David Codyre for

Please see advert below:

Kia ora   Supply Issue:   We are writing to inform you that due to shipping delays, Sandoz expects to run out of ticagrelor 90mg tab by mid-March 2026.   Key Dates: It is estimated that ticagrelor 90mg tab (Sandoz) stock will be depleted by mid-March An alternative brand Ticagrelor Mylan 90mg tab was listed from 1 March 2026   Key messages: Ticagrelor Mylan is from the Italian market. The box will be over labelled with English text, and the blister packs have Italian text. Ti

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 06 March 2026. It includes information on:  New updates Resolved Supply Issues Changes to antiretroviral dispensing – effective 1 March 2026 From 1 March 2026, all listed  antiretroviral  (Community Schedule)  treatments changed to 90‑day dispensing and may be prescribed and dispensed accordingly where appropriate.  Supply issue: ticagrelor tab 90 m

Please see Research Review edition attached

Please see Research Review edition attached

Pharmac has asked suppliers to notify us early of any supply risks, so we can act sooner and support ongoing access to medicines and medical devices. Read more Have your say We’re consulting on upcoming changes to how the Pharmaceutical Schedule will work. Changes to how the Pharmaceutical Schedule will work  (consultation closes 13 March 2026) New medicine supply notices   Proctosedyl (suppositories)  Unfortunately, AFT (the supplier) has run out of Proctosedyl suppositories

Pharmac is seeking feedback on a proposal to fund letermovir, a medicine that helps prevent serious viral infection in people with very weak immune systems. Under this proposal, letermovir would be funded from 1 May 2026 for people who have had a stem cell transplant, as well as a small number of other people with severe immunosuppression who cannot use other funded antiviral medicines. We have heard from clinicians involved in stem cell transplant care and from Pharmac’s cli

Kia ora   The March 2026 edition of Prescriber Update  is now available on the Medsafe website. Please can you share it with your networks.   Kind regards   Medsafe Pharmacovigilance Team

Issue 337 - 5 March 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here . You can also access other recent issues of the digest here. If you have any queries, please email us at  library@health.govt.nz . Article Access For articles that aren't

A randomized trial compared oral ivermectin with 5% permethrin for treating scabies in index cases and household clusters of up to eight people 1 . Ivermectin 200 µg/kg was taken with food on days 0 and 10, while permethrin was applied head-to-toe, including hair, genitalia, and children’s faces, left on overnight, and washed off after at least eight hours. Emollients and textile decontamination were advised. Children under 15 kg received permethrin only.  Cluster-level cur

Kia ora koutou,   This is a quick reminder that our initial consultation questionnaire regarding the review of Ngā paerewa Health and disability services standard 2021  (Ngā Paerewa) will close in two weeks on 16 March 2026 .   If you have already submitted your feedback, thank you for your time and please disregard this email.   We acknowledge that this is a relatively short consultation window. We want to reassure you that this is an initial questionnaire only. Its purpose

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 27 February 2026. It includes information on:  New updates Resolved Supply Issues Changes to Antiretroviral Dispensing – Effective 1 March 2026 From 1 March 2026, all listed antiretroviral  (community schedule)  treatments will default to 90‑day dispensing and may be prescribed and dispensed accordingly where appropriate.  Improving access to treatm

We are writing to remind you that clomipramine capsules 10mg will be delisted (no longer funded.)   Key Points: The delist date from the Pharmaceutical Schedule is 1 April 2026 Clomipramine 25mg tablets will remain available and listed on the Pharmaceutical Schedule Please continue to consider alternative options for patients that require the lower 10mg dose     Please share this information with your colleagues and within your networks. If you have any queries, please contac

We’re consulting on upcoming changes to how the Pharmaceutical Schedule will work. Changes to how the Pharmaceutical Schedule will work  (consultation closes 13 March 2026) New medicine supply notices Pedialyte: Claiming update   Urgent action required: Pharmacies need to check any claims they made for Pedialyte in February 2026. See the website for more details. Ticagrelor (Tab 90 mg)  (Pharmacode: 2638770) The supplier anticipates running out in mid-March. A S29 alternative